Traxion Sab De Cv Ord Shs GRPOF

Important short term value creating milestones

[Golddetector]

Below are the main evens for q3 and q4 as per presentation on may 2021: many ppl think reduvo sales in q4 is most important even but IMO QIXLEEF q3 update and ard003 are way more important. If QIXLEEF pass ph ii that drug itself will worth 500 millions us at least. With positive indicators in place I think we have low risk but I think investors are looking for a stronger confirmation to de-risk the investment. We are getting close. Gl longs 

Short-Term Value-Creating Milestones

QIXLEEF - PLENITUDE:

Q2: ACCELERATE PATIENT ENROLMENT

Q3: RECEIVE OPINION FROM EMA – MALTA COMPETENT AUTHORITY

QIXLEEF – REBORN1:

Q2: 1ST PATIENT IN

Q3: INTERIM ANALYSIS

Q3: RECEIVE OPINION FROM EMA – MALTA COMPETENT AUTHORITY Q1-22: END OF ENROLMENT

ARDS-003:

Q4: LAST HEALTHY VOLUNTEER Q1-22: LAST PATIENT IN

CAU M Z:

BRIDGE TO QIXLEEF

R ED U VO :

Q4:DIN EXPECTED

ENJOUCA :

MARKET LAUNCH DATES: CANADA Q4 2021, AUSTRALIA Q1 2022, GERMANY Q2 2022

[DONOOW]

strange ... I post what TBP say about risk of dilution and bankruptcy and there is someone talking about risks and how the risk is low .... Guy show yourself

[Golddetector]

[DONOOW]

thats an example of big hopes VS low performance and the reality is its just to attract investors ... We are really disappointed and look for facts. Enough talking Guy we are not willing to see your face .bring approvals or go f..cker

[DootDootDoot]

This post has been removed in accordance with Community Policy

[Caper18]

Malta is for European approval similar to FDA and HC